GSK has announced a new licensing deal with CureVac to gain full rights for the development, manufacturing, and international commercialization of messenger RNA (mRNA) candidate vaccines for influenza and Covid-19. This collaboration will allow both companies to focus their respective investments and activities in mRNA development.
